Marjorie Eiref, Head of Operations for Neuroscience Research at Novartis, describes how her family medical history has impacted her career.

The most lethal strain could be eliminated by 2030, but major hurdles remain.

Novel PRC2 inhibitor changes the expression of hundreds of genes in lab model

A Cell & Gene production unit staffed by a highly trained team at Novartis will soon begin operating in Stein, Switzerland.

Research exploring the first visible changes in the brain is helping scientists evaluate new potential treatments for Alzheimer’s.

Industry labs find that, contrary to earlier evidence, KRAS-driven tumors are not addicted to autophagy.

Learn how Novartis researchers are working to outsmart tumors.

Learn about the career of our Global Medical Affairs Head for Solid Tumors and Rare Diseases.